Garde Capital, Inc. Crispr Therapeutics Ag Transaction History

Garde Capital, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 25, 2022	SELL	$70.09 - $111.29 $64,202 - $101,941	-916 Closed	0 $0
Q3 2021 Nov 17, 2021	BUY	$110.2 - $156.64 $1,212 - $1,723	11 Added 1.22%	916 $103,000
Q2 2021 Aug 19, 2021	BUY	$100.84 - $161.89 $5,647 - $9,065	56 Added 6.6%	905 $147,000
Q1 2021 May 24, 2021	BUY	$110.72 - $210.04 $94,001 - $178,323	849 New	849 $103,000

485

57.5M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.12B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Garde Capital, Inc., based on Form 13F filings with the SEC.

Stay updated on Garde Capital, Inc. with notifications on news.